ReleaseWire Connect

GBI Research, a leading business intelligence provider, has released its latest research, “OLED Displays and Lighting Market to 2020 - Technological Innovations Lead to Cost Efficient Products and New Aesthetics”. The report gives an in-depth analysis of the global Organic Light Emitting Diodes (OLED) market for displays and lighting, covering four major regions – North America (USA and Canada), Europe, Asia–Pacific. The report covers market revenue forecasts for the OLED market (Displays and Lighting) from 2005-2020 It also provides market revenues breakdown for displays by application types; Cell Phones, Televisions, IT Monitors and Others and technology type; Passive Matrix Organic Light Emitting Diode (PMOLED) Displays and Active Matrix Organic Light Emitting Diode (AMOLED) Display.

GBI Research, the leading business intelligence provider, has released its latest research, “Ophthalmology Therapeutics Market to 2017 - Protein Kinase Inhibitors and Prostaglandin H-Synthase Inhibitors to Drive Diabetic Retinopathy Market”, which provides insights into the global ophthalmology therapeutics market forecast until 2017. The report provides an in-depth analysis of the six therapeutic indications of ophthalmology, namely glaucoma, allergic conjunctivitis, dry eye syndrome, diabetic macular edema, diabetic retinopathy and wet age macular degeneration. The report also examines the ophthalmology therapeutics treatment usage patterns for the covered indication. In addition, the report includes insights into the ophthalmology R&D pipeline. GBI Research analysis shows that the overall global ophthalmology market for glaucoma, allergic conjunctivitis, dry eye syndrome, diabetic macular edema, diabetic retinopathy and wet age macular degeneration was valued at $10.3 billion in 2010. The market is expected to grow at a CAGR of 3.6% for the forecast period and will reach $13.2 billion by 2017. The global market revenues are expected to increase due to the introduction of new molecules which are currently in the regulatory filing stage and those in the later stages of development.

GBI Research, the leading business intelligence provider, has released its latest research “Metabolic Disorders Therapeutics Market to 2017 – Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value”, which provides insights into metabolic disease therapeutics marled until 2017. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. The report provides an in-depth analysis of the major metabolic diseases including Diabetes, Obesity and Dyslipidemia. The report also provides the share of generics in global metabolic diseases as well as in each indication market. It also provides the treatment algorithm flow for each three indications. The report examines the global metabolic diseases treatment usage patterns. In addition, the geographical distribution of metabolic diseases and market across the US, the top five countries of Europe and in Japan are provided in the report. The report also includes insights into the metabolic diseases R&D product pipeline and explores the competitive landscape including major players in metabolic disorder therapeutics market. Finally, the report also includes analysis on Mergers and Acquisitions (M&As) and licensing agreements that took place in metabolic disorder therapeutics market.

GBI Research’s report ‘Clinical Trial Recruitment in Dermatology - Most Trials Focus on Atopic Dermatitis While Acne Vulgaris Has Highest Patient Numbers’ provides an in-depth analysis of the current patient recruitment scenario for major indications under dermatology. The report analyzes a number of clinical trials conducted for major indications. It provides information about the total number of clinical trials conducted by phase, geography, major sponsors and clinical trials per year. An analysis of the total number of patients recruited for major indications is given. The report analyzes total number of patients recruited by phase of clinical trial, geography and major sponsors. An analysis of the average number of patients recruited per trial per year for various indications is also given. Clinical trials are being conducted on dermatological diseases in order to find better treatment options. There has been an increase in the number of clinical trials conducted due to a rise in the prevalence of dermatology disorders. A clinical trial is one of the most critical parts of the drug development process.

GBI Research, the leading business intelligence provider, has released its latest research, “Contraceptives Market to 2017” which provides insights into global contraceptives market and market forecast until 2017. Report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. The report provides an in-depth analysis of the contraceptives used. The report provides an in-depth analysis of the oral contraceptives, topical contraceptive, injectable contraceptive, intrauterine devices, condoms and vaginal rings. The report examines the oral, topical and injectable contraceptives treatment usage patterns. The report also includes insights into the contraceptives R&D product pipeline and explores the competitive landscape including major players in contraceptives market.

GlobalData, the industry analysis specialist, has released its new report, “Atopic Dermatitis Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Atopic Dermatitis Therapeutics market. The report identifies the key trends shaping and driving the global Atopic Dermatitis Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Atopic Dermatitis Therapeutics sector.

GlobalData’s new report ‘Eagle Ford Shale in the US, 2011 - Oil Shale Market Analysis and Forecasts to 2020’ analyzes the recent activities in the Eagle Ford shale play in the US.

This report includes a detailed analysis of the current investment climate in the country’s power sector and over the next decade across 6 broad parameters. Each parameter has a weight assigned, and a weighted average score is calculated to obtain the final country ranking in that region. The study also maps the relative ranking of the key countries in the region according to the current investment opportunities in the country and that by 2020.

GlobalData, the industry analysis specialist, has released its new report, “Rheumatoid Arthritis Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global rheumatoid arthritis therapeutics market. The report identifies the key trends shaping and driving the global rheumatoid arthritis therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global rheumatoid arthritis therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.